Francesco Schettini, Alessandra Fontana, Federica Gattazzo, Carla Strina, Manuela Milani, Maria Rosa Cappelletti, Valeria Cervoni, Lorenzo Morelli, Giuseppe Curigliano, Valerio Iebba , Daniele Generali
Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain b Translational Genomics and Targeted Therapies in Solid Tumors, Fundació de Recerca Clínic Barcelona-Institut d′Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain c Faculty of Medicine, University of Barcelona, Barcelona, Spain d Department for Sustainable Food Process-DiSTAS, Università Cattolica del Sacro Cuore, Piacenza, Italy e Department of Medicine, Surgery and Health Sciences, University of Trieste, Cattinara Hospital, Trieste, Italy f Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy g Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy h Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Cremona, Italy
Cyclin-dependent kinase (CDK)4/6-inhibitors with endocrine therapy represent the standard of treatment of hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Gut microbiota seems to predict treatment response in several tumour types, being directly implied in chemotherapy resistance and development of adverse effects. No evidence is available on gut microbiota impact on efficacy of HR+ breast cancer treatment.
Biomarker; Cyclin-dependent kinase (CDK)4/6- inhibitors; Metastatic breast cancer;